Haemodynamic effects of a single intravenous dose of lorcainide in patients with heart disease
| Autor: | Wolfgang Kasper, F. Kersting, H. Bechtold, Eberhard Jähnchen, H. Just, Thomas Meinertz |
|---|---|
| Rok vydání: | 1980 |
| Předmět: |
Adult
Male medicine.medical_specialty Cardiac output Time Factors Heart Diseases Heart disease Benzeneacetamides Diastole Hemodynamics Blood Pressure Lorcainide Piperidines Internal medicine medicine Humans Pharmacology (medical) Cardiac Output Aged Pharmacology Ejection fraction business.industry Heart General Medicine Middle Aged medicine.disease Myocardial Contraction medicine.anatomical_structure Anesthesia Vascular resistance Ventricular pressure Cardiology Female Vascular Resistance business Anti-Arrhythmia Agents medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 18:461-465 |
| ISSN: | 1432-1041 0031-6970 |
| DOI: | 10.1007/bf00874656 |
| Popis: | The cardiovascular effects of a single i.v. dose (2 mg/kg over 5 min) of lorcainide were studied in 14 patients with heart disease. In the haemodynamic part of the study (6 patients), the aortic and pulmonary systolic, diastolic and mean pressures, left ventricular systolic and end-diastolic pressures, cardiac output and the rate of rise of left ventricular pressure were measured before and for 30 min after administration of the drug. Lorcainide produced a slight and short-lasting decrease in the aortic and pulmonary systolic pressures, and all other pressure values remained unchanged. The cardiac output and systemic vascular resistance were not altered by lorcainide. It consistently depressed the rate of rise of left ventricular pressure (maximum mean decrease 19%). In the angiographic part of the study (8 patients), the ejection fraction and the mean velocity of circumferential fiber shortening were measured before and 5 min after lorcainide. In all but one patient, lorcainide decreased the ejection fraction (mean decrease 11.6%), and the mean velocity of circumferential fiber shortening was uniformly diminished by lorcainide (mean decrease 29.7%). Thus, lorcainide moderately impaired myocardial performance in patients with normal and reduced left ventricular function without producing hypotensive side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink